Global Hypoglycemia Drugs Market Forecast and Analysis 2021-2030 Report: Focus on Diabetic Hypoglycemia and Post-Bariatric Surgery (PBH) Hypoglycemia –


DUBLIN – (COMMERCIAL THREAD)–The “Hypoglycemia – Global Drug Forecasts and Market Analysis to 2030” the report was added to offer.

This report will focus on diabetic hypoglycemia and post-bariatric surgery hypoglycemia (BPH). There is currently no approved treatment for PBH.

The hypoglycemia therapy in 7MM market will grow from $ 423.5 million in 2020 at a compound annual growth rate (CAGR) of 4.8% to $ 657.1 million by 2030. In particular, the US market will contribute the most to the growth of the hypoglycemia market, contributing $ 399.8M in sales in 2020 (94% of the hypoglycemia market) and $ 577.1M in 2030 (85.5% of the hypoglycemia)

The launch of the new therapeutic formulations of glucagon will be the main driver of growth during the forecast period, with the first stable liquid glugaons to be launched during the forecast period in addition to increased uptake of glucagon. nasal glucagon, Baqsimi. Other major drivers of the hypoglycemia market include the increased prevalence of T1D diagnoses, and the adoption of new formulations of glucagon will result in the use of therapy over inpatient treatment.

Based on The Editor’s epidemiological analysis, diagnosed incident cases of severe hypoglycemia attributed to T1D will increase by 4.7% over the next decade, from 17,359 cases in 2020 to 18,180 cases in 2030 , at an annual growth rate (AGR) of 0.5. % per year in the seven main pharmaceutical markets (7 MM) covered in this report, the United States, the 5 EU (France, Germany, Italy, Spain and United Kingdom) and Japan.

Incident diagnosed cases of severe hypoglycemia attributed to T2DM will increase by 1.4% over the next decade, from 173,085 cases in 2020 to 175,530 cases in 2030 with an AGR of 0.1% in 7MM. Incident diagnosed cases of PBH will increase by 18.7% over the next decade, from 50,227 cases in 2020 to 59,627 cases in 2030 with an AGR of 1.7% in the 7MM.

The consensus among physicians surveyed regarding the current landscape of hypoglycemia treatment is that there are enough treatments to treat severe hypoglycemia, and that there are few unmet needs for hypoglycemia that can be treated. therapeutically. Key Opinion Leaders (KOL) interviewed by

The main unmet need is that there are no adequate treatments for nondiabetic hypoglycemia. Other unmet needs include the lack of affordable treatments, the lack of practical treatments, and the prevalence of unawareness of hypoglycemia.

Research suggests that the future level of fulfilling these unmet needs will be medium-high, and that there are not many opportunities for drug developers to enter the severe hypoglycemia market, but there is an opportunity to tackle the non-diabetic hypoglycemia market. .


  • The diagnosed incidence of hypoglycemia and severe hypoglycemia is expected to increase over the 10-year forecast period due to the increasing prevalence of T1D and T2DM.

  • The increased use of Baqsimi and stable liquid glucagons will increase the number of patients who can treat their hypoglycemia outside of a hospital setting and improve their overall quality of life. These drugs are expected to have a high annual cost of treatment (ACOT), a factor that will contribute to significant profitability.

  • The growing trend towards blood glucose monitoring in the treatment and management of insulin-dependent diabetic patients will have an impact on which therapies will be successful in the market. Increased monitoring will allow patients to detect hypoglycemia before it gets worse. For T1D, the trend towards closed-loop pump systems, such as an artificial pancreas, offers dual hormone pumps the opportunity to use glucagon to actively manage hypoglycemia.

  • Severe hypoglycemia is adequately treated and there is little room for new entrants. The launch of the first inhalable and fluid stable glucagons facilitated rescue treatment. The most recognizable needs that the larger market must meet is that insulins always cause hypoglycemia and that non-diabetic hypoglycemia requires targeted treatments.

Main topics covered:

1 Hypoglycemia: executive summary

1.1 The hypoglycemia market will reach 675.1 million by 2030

1.2 New players in hypoglycemia focus on increasing ease of use and integration with technologies

1.3 There are few unmet needs for hypoglycemia that can be treated therapeutically

1.4 Pipeline therapies and device integration could have a significant impact on the incidence of severe events

1.5 What do doctors think?

2 Presentation

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Overview of the disease

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or scaffolding systems

4 Epidemiology

4.1 Context of the disease

4.2 Risk factors and co-morbidities

4.3 Global and historical trends

4.3.1 Diagnosed incidence of hypoglycemia attributed to type 1 diabetes

4.3.2 Diagnosed incidence of hypoglycemia attributed to type 2 diabetes

4.4 7MM forecasting methodology

4.5 Epidemiological forecast of hypoglycemia (2020-2030)

4.6 Debate

5 Disease management

5.1 Overview of diagnosis and treatment

5.2 Self-management practices of patient hypoglycemia through the 7MM

5.3 Practices for treating severe hypoglycemia through 7MM

5.3.1 Hospitalization on 7MM markets

5.4 Management of non-diabetic hypoglycemia within 7 MM

6 Competitive assessment

6.1 Overview

7 Unmet needs and assessment of opportunities

7.1 Overview

7.2 Treatments for non-diabetic hypoglycemia

7.3 Prevention of severe hypoglycemia

7.4 Ease of administration of glucagon

7.5 Cost of glucagon

7.6 Sensitization to hypoglycemia

8 R&D strategies

8.1 Overview

8.2 clinical trial design

9 Pipeline assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline valuation analysis

10.1 Overview

10.2 Competitive assessment

11 current and future players

12 Market Outlook

13 Annex

Companies mentioned

  • Novo Nordisk

  • Eli lilly

  • Zealand Pharma

  • Xeris Pharmaceuticals

  • Eiger Biopharmaceuticals

  • Fresenius Kabi

  • Amphastar Pharma

  • Fuji Pharma

  • Kaigen Pharma

For more information on this report, visit


Comments are closed.